Aclaris Therapeutics, Inc. (ACRS)

Market Cap	310.95M +97.9%
Revenue (ttm)	7.83M -58.2%
Net Income	-64.92M
EPS	-0.53
Shares Out	108.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,356,196
Open	3.080
Previous Close	3.130
Day's Range	2.850 - 3.140
52-Week Range	1.050 - 4.890
Beta	0.87
Analysts	Strong Buy
Price Target	9.75 (+239.72%)
Earnings Date	Feb 26, 2026

About ACRS

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatmen...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 7, 2015
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: ACRS
• Website: https://www.aclaristx.com

Financial Performance

In 2025, Aclaris Therapeutics's revenue was $7.83 million, a decrease of -58.19% compared to the previous year's $18.72 million. Losses were -$64.92 million, -50.84% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for ACRS stock is "Strong Buy." The 12-month stock price target is $9.75, which is an increase of 239.72% from the latest price.

Price Target

$9.75

(239.72% upside)

Analyst Consensus: Strong Buy